DOXLIEVA-L 50 MG (Doxorubicin Hydrochloride Liposomal Injection 50 mg/25 mL) is a prescription anticancer medicine containing Doxorubicin Hydrochloride 50 mg in a liposomal formulation. It belongs to the Anthracycline class of anticancer medicines and is used in the treatment of several cancers.

The liposomal formulation encapsulates doxorubicin within microscopic lipid particles called liposomes. This formulation alters the distribution of the medicine in the body and allows doxorubicin to reach tumor tissues while potentially reducing some of the toxicity associated with conventional doxorubicin.

Doxorubicin works primarily by interfering with DNA replication and repair and by inhibiting topoisomerase II, an enzyme required for cancer cell division. It can also generate free radicals that contribute to cancer cell damage. These actions inhibit the growth and multiplication of cancer cells.

DOXLIEVA-L 50 MG may be used in the treatment of ovarian cancer, AIDS-related Kaposi's sarcoma, multiple myeloma in combination therapy, and certain other cancers, depending on the approved indication and treatment protocol.

The medicine is administered by intravenous infusion under the supervision of qualified healthcare professionals experienced in oncology treatment.

DOXLIEVA-L 50 MG is commonly used in:

• Ovarian Cancer
• AIDS-Related Kaposi's Sarcoma
• Multiple Myeloma in Combination Therapy
• Advanced Malignancies
• Selected Solid Tumors
• Combination Oncology Treatment Protocols

Patients receiving liposomal doxorubicin require regular monitoring of blood counts, liver function, cardiac health, and overall clinical condition.

DOXLIEVA-L 50 MG (Doxorubicin Hydrochloride Liposomal Injection 50 mg/25 mL) is used as part of specific oncology treatment regimens.

Common Uses

1. Ovarian Cancer

Liposomal doxorubicin may be used for advanced ovarian cancer, particularly when the disease has progressed following previous chemotherapy.

2. AIDS-Related Kaposi's Sarcoma

It is an established treatment option for AIDS-related Kaposi's sarcoma.

3. Multiple Myeloma

Liposomal doxorubicin may be used in combination with other medicines for selected patients with multiple myeloma.

4. Advanced Cancer

It may be incorporated into treatment protocols for selected advanced or metastatic malignancies according to the treating oncologist's recommendation.

5. Combination Therapy

The medicine may be administered with other anticancer medicines when clinically appropriate.

How DOXLIEVA-L 50 MG Works

Doxorubicin is an Anthracycline Anticancer Agent.

DOXLIEVA-L works through several mechanisms:

• Inhibits topoisomerase II
• Interferes with DNA replication
• Disrupts DNA repair
• Damages cancer-cell DNA
• Interferes with RNA and protein synthesis
• Generates free radicals
• Inhibits cancer cell multiplication
• Promotes cancer cell death

The liposomal formulation changes the distribution and circulation of doxorubicin in the body and is designed to modify its delivery to tissues.

Like all anticancer medicines, DOXLIEVA-L 50 MG may cause side effects. Their severity and frequency vary from patient to patient.

Common Side Effects

1. Fatigue

Tiredness and weakness may occur during treatment.

2. Nausea

Some patients may experience nausea or digestive discomfort.

3. Low Blood Cell Counts

Treatment can reduce white blood cells, red blood cells, or platelets.

4. Mouth Sores

Oral ulcers or inflammation of the mouth may occur.

5. Hand-Foot Syndrome

Redness, swelling, tenderness, pain, or peeling of the palms and soles may occur.

6. Hair Loss

Hair thinning or hair loss may occur in some patients.

7. Diarrhea

Changes in bowel habits may develop.

8. Skin Reactions

Rash, redness, or other skin changes may occur.

9. Loss of Appetite

Some patients may experience reduced appetite during treatment.

Serious Side Effects

Seek immediate medical attention if you experience:

• Severe allergic or infusion-related reactions
• Difficulty breathing
• Severe infection or persistent fever
• Unusual bleeding or bruising
• Severe skin reactions
• Significant swelling
• Symptoms of heart problems such as chest pain or unusual shortness of breath
• Severe liver-related symptoms

Patients should promptly report unusual or severe symptoms to their healthcare provider.

The dosage of DOXLIEVA-L 50 MG must be determined by a qualified oncologist based on the indication, treatment protocol, body surface area, organ function, previous treatments, and individual patient response.

The 50 mg/25 mL presentation does not mean that the entire vial should automatically be administered to every patient. The required dose and infusion schedule are individualized by the treating healthcare professional.

Factors Affecting Dosage

1. Type of Cancer

Different cancers require different dosing schedules.

2. Body Surface Area

Dosage may be calculated according to body surface area for the relevant indication.

3. Liver Function

Dose modification may be required in patients with hepatic impairment.

4. Previous Treatment

Previous chemotherapy and cumulative anthracycline exposure may influence treatment decisions.

5. Blood Counts

Treatment may need to be delayed or adjusted if blood cell counts are too low.

6. Treatment Response and Toxicity

The oncologist may modify treatment according to effectiveness and adverse effects.

Important Administration Instructions

• DOXLIEVA-L should be administered by intravenous infusion by trained healthcare professionals.
• It should not be administered as a rapid intravenous injection or intramuscularly.
• Follow the prescribed infusion schedule exactly.
• Patients should be monitored for infusion-related reactions.
• Regular blood tests and clinical evaluations are important during therapy.
• Do not alter or discontinue treatment without medical advice.

Precautions Before Using DOXLIEVA-L 50 MG

Before treatment, inform your doctor if you have:

• Heart disease or previous heart problems
• Liver disease
• Low blood cell counts
• Previous treatment with anthracyclines
• Previous severe reactions to doxorubicin or liposomal medicines
• Any active infection
• Any known allergy to the ingredients

Important Monitoring

Patients receiving liposomal doxorubicin may require:

• Complete blood count
• Liver function tests
• Cardiac assessment when clinically indicated
• Monitoring for infusion reactions
• Skin and hand-foot syndrome assessment
• Regular oncology follow-up

Tell your healthcare professional about all prescription medicines, over-the-counter medicines, supplements, and herbal products you use.

Pregnancy should be avoided during treatment because doxorubicin may cause fetal harm. Breastfeeding is generally not recommended during treatment; discuss appropriate precautions with your healthcare professional.

Storage Instructions

• Store according to the manufacturer's recommended conditions.
• Protect from light as directed on the product labeling.
• Do not freeze unless specifically permitted by the manufacturer's instructions.
• Keep out of reach of children.
• Handle and transport according to appropriate pharmaceutical requirements.

Why Choose DOXLIEVA-L 50 MG?

• Contains Doxorubicin Hydrochloride 50 mg/25 mL
• Liposomal formulation of an established anthracycline medicine
• Used in specific oncology treatment protocols
• Applicable in selected ovarian cancer and Kaposi's sarcoma regimens
• May be incorporated into combination treatment for multiple myeloma
• Designed for controlled intravenous administration
• Manufactured under stringent pharmaceutical quality standards
• Supports modern oncology treatment programs

Frequently Asked Questions (FAQs)

What is DOXLIEVA-L 50 MG used for?

DOXLIEVA-L is used in specific treatment regimens for ovarian cancer, AIDS-related Kaposi's sarcoma, and selected multiple myeloma treatment protocols.

What is liposomal doxorubicin?

Liposomal doxorubicin is a formulation in which doxorubicin is enclosed within lipid-based particles called liposomes. This changes the medicine's distribution and pharmacokinetic properties.

Is DOXLIEVA-L 50 MG chemotherapy?

Yes. Doxorubicin is an anthracycline chemotherapy medicine.

How is DOXLIEVA-L administered?

It is administered by intravenous infusion under the supervision of trained healthcare professionals.

Can DOXLIEVA-L affect blood counts?

Yes. It can cause decreases in blood cell counts, which is why regular blood monitoring is important.

Can DOXLIEVA-L affect the heart?

Anthracyclines can cause cardiac toxicity. Your doctor may assess cardiac function based on your medical history and cumulative treatment exposure.

Can DOXLIEVA-L cause hand-foot syndrome?

Yes. Palmar-plantar erythrodysesthesia, commonly called hand-foot syndrome, can occur with liposomal doxorubicin.

Should DOXLIEVA-L be administered under medical supervision?

Yes. It should only be administered by qualified healthcare professionals experienced in oncology treatment.